In view of this situation, in order to reduce the burden on the elderly, the National Medical Insurance Administration will begin centralized mass procurement of artificial hip joints and artificial knee joints nationwide in 2021. The medical insurance department will count the number of people who perform this kind of surgery in hospitals across the country, and conduct centralized bidding and procurement of the types of artificial hip joints needed. The companies participating in the bidding are basically the same as those that originally provided these consumables. After winning the bid, the medical insurance department will directly settle the settlement with the enterprise for the hip joints and knee joints produced by the enterprise. There is no intermediate circulation link and middlemen to make the difference, and the enterprise also reduces the cost of sales. After centralized procurement, the price of artificial hip joints dropped from 35,000 yuan to about 7,000 yuan, and the price of artificial knee joints dropped from 32,000 yuan to about 5,000 yuan. The average price reduction reached 82%. Moreover, many of the manufacturing companies involved in this centralized procurement are the same as those before the centralized procurement, and the products are all the same, so the quality can be guaranteed.
What is the effect after centralized procurement? Let’s first look at the improvements. There is no doubt that the benefits brought by the price drop are easy to see. The same surgery can be tens of thousands cheaper before and after centralized procurement. Now for this kind of surgery, the price you can bear after being reimbursed by medical insurance is only a few thousand yuan. Some people need to replace their hip joints on both sides. The hip joints cost more than 20,000 yuan before the centralized procurement came into effect. After the centralized procurement, the total cost of the same surgery and the same materials only cost more than 7,000 yuan. This is The most obvious benefit.
For the medical insurance fund, a significant reduction in materials can also reduce the expenditure of the medical insurance fund. The reduction of the expenditure of the medical insurance fund can expand the scope of medical insurance reimbursement and increase the proportion of medical insurance reimbursement, and can further reduce the cost of patients. This is a win-win situation.
However, although centralized purchasing has allowed patients to enjoy the dividends brought by the reform and reduced medical insurance expenditures, it has also touched the interests of some people, including pharmaceutical representatives , some hospitals, and some doctors. Therefore, it is more difficult to implement and promote the reform at the beginning. After the centralized procurement of consumables is available, a small number of doctors will recommend some non-centralized procurement materials. For the medical industry with extremely high professional barriers, most of them will Some patients really just have to listen to their doctors. If there are materials purchased centrally, the reimbursement rate for non-centrally purchased medical insurance will be very low. For example, if a hip joint purchased centrally costs 7,000 yuan, no matter what company produces the hip joint, it can only be reimbursed at a price of 7,000 yuan at most. In this way This will cause the patient's costs to be even higher than before the centralized procurement, which is very helpless.
However, this will always get better gradually. While the medical reform was still in progress, there were some detours after the founding of New China. However, we are still moving forward steadily in the reform and slowly getting better. The same is definitely true for the medical industry, as the reform deepens. The price will always come down.
